In a report released today, Steve Scala from Cowen & Co. maintained a Buy rating on AbbVie (ABBV), with a price target of $110. The company’s shares closed yesterday at $87.73.
Scala has an average return of 1.3% when recommending AbbVie.
According to TipRanks.com, Scala is ranked #1076 out of 4912 analysts.
Currently, the analyst consensus on AbbVie is a Hold with an average price target of $97.63, representing an 11.3% upside. In a report issued on November 6, Argus Research also maintained a Buy rating on the stock with a $115 price target.
.
See today’s analyst top recommended stocks >>
Based on AbbVie’s latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $8.24 billion and net profit of $2.74 billion. In comparison, last year the company earned revenue of $7 billion and had a net profit of $1.62 billion.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
